Growth Hormone Research Market

Sermorelin

A GHRH analogue with older clinical and diagnostic history that now appears frequently in the research and wellness peptide market.

GHRHGrowth HormoneResearch Market

Also referenced as: Sermorelin Acetate, Geref

Also appears in: Muscle Growth

Price compare
73 tracked offers across 73 vendors · 14 dosages
Best trust-adjusted value: Southern Aminos · Moderate trust · $2.70/mg
From
$2.70/mg
Status
Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Category
Growth Hormone

Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.

Aliases
2

Sermorelin Acetate, Geref

Signal depth
Medium

No FDA label signal · 42 trials · 33 PubMed results

Preclinical
Research evidence

Current evidence for Sermorelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Sermorelin has no clinical trials that name it and 33 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data
Lab / animal only
Trial quality
No human trials
Outcomes
No human trials
Replication
Multiple papers
Literature
High-impact
The Journal of Clinical Endocrinology & Metabolism · 52 citations Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. BioDrugs · 31 citations Sermorelin Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Journal Article A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. Journal Article Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What sermorelin is

Sermorelin is a growth hormone-releasing hormone analogue that sits closer to the clinical side of the GH category than many generic secretagogues. It is still common in vendor listings and wellness-adjacent peptide conversations.

Why it matters

It helps bridge the gap between older hormone-therapy language and today’s research-market catalog culture.

Regulatory context

Sermorelin products widely sold through peptide vendors should be understood as unapproved retail-market offerings, not as interchangeable with any prior medical or diagnostic context.

Practical reading note

Sermorelin is a good reminder that a compound can have a more serious historical footing than the average peptide listing while still being marketed in ways that go far beyond that footing.